Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
CLRB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.04%108.241.1%$605.41m
GILDGilead Sciences, Inc.
-2.93%74.340.9%$540.78m
AMGNAmgen Inc.
-1.39%174.921.1%$476.57m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%383.122.7%$338.65m
BIIBBiogen Inc.
-2.17%323.551.2%$316.85m
ALXNAlexion Pharmaceuticals, Inc.
-0.40%113.091.9%$255.42m
BLUEBluebird Bio, Inc.
-0.30%184.3516.1%$198.90m
VRTXVertex Pharmaceuticals Incorporated
-1.57%142.531.9%$197.41m
ILMNIllumina, Inc.
-1.73%210.853.5%$160.91m
ALNYAlnylam Pharmaceuticals, Inc
-0.96%123.6610.0%$160.42m
NKTRNektar Therapeutics
-2.79%55.056.1%$153.38m
AAgilent Technologies, Inc.
-0.26%66.511.5%$152.00m
INCYIncyte Corporation
-2.17%95.972.5%$129.88m
BMRNBioMarin Pharmaceutical Inc.
-0.15%88.534.4%$100.67m
JUNOJuno Therapeutics, Inc.
-6.83%44.1713.5%$94.92m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.